Stock ICLR ICON PUBLIC LIMITED COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
308.3 USD +2.74% Intraday chart for ICON Public Limited Company +6.97% +8.92%
Apr. 26 UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating MT
Apr. 25 Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,239 10,290 25,209 15,860 23,304 25,492 - -
Enterprise Value (EV) 1 9,018 9,797 29,891 20,223 26,700 27,783 26,622 25,377
P/E ratio 25.4 x 31.7 x 138 x 31.7 x 38.3 x 31.3 x 25.8 x 22.4 x
Yield - - - - - - - -
Capitalization / Revenue 3.29 x 3.68 x 4.6 x 2.05 x 2.87 x 2.95 x 2.75 x 2.56 x
EV / Revenue 3.21 x 3.5 x 5.45 x 2.61 x 3.29 x 3.22 x 2.87 x 2.55 x
EV / EBITDA 18.2 x 20.6 x 30.8 x 13.7 x 15.8 x 15 x 13.2 x 11.6 x
EV / FCF 24.9 x 19 x 40.6 x 48 x 26.2 x 22.9 x 18.5 x 16.2 x
FCF Yield 4.01% 5.28% 2.46% 2.08% 3.82% 4.37% 5.4% 6.16%
Price to Book 5.71 x 5.56 x 3.13 x 1.87 x 2.53 x 2.53 x 2.29 x 2.07 x
Nbr of stocks (in thousands) 53,641 52,775 81,398 81,645 82,327 82,684 - -
Reference price 2 172.2 195.0 309.7 194.2 283.1 308.3 308.3 308.3
Announcement Date 2/19/20 2/24/21 2/22/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,806 2,797 5,481 7,741 8,120 8,640 9,284 9,962
EBITDA 1 495 475.7 970 1,479 1,694 1,848 2,017 2,196
EBIT 1 433.4 409.6 655 1,373 1,568 1,713 1,869 2,046
Operating Margin 15.45% 14.64% 11.95% 17.74% 19.31% 19.82% 20.14% 20.53%
Earnings before Tax (EBT) 1 427 381.2 196.7 567.9 624.5 948.4 1,137 1,275
Net income 1 374 332.3 153.2 505.3 612.3 839.5 1,019 1,170
Net margin 13.33% 11.88% 2.79% 6.53% 7.54% 9.72% 10.98% 11.75%
EPS 2 6.790 6.150 2.250 6.130 7.400 9.849 11.96 13.76
Free Cash Flow 1 361.9 516.9 735.4 421.2 1,020 1,215 1,438 1,562
FCF margin 12.9% 18.48% 13.42% 5.44% 12.57% 14.06% 15.48% 15.68%
FCF Conversion (EBITDA) 73.12% 108.66% 75.82% 28.47% 60.23% 65.76% 71.27% 71.13%
FCF Conversion (Net income) 96.77% 155.54% 480.07% 83.35% 166.63% 144.74% 141% 133.49%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/19/20 2/24/21 2/22/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,885 1,902 1,935 1,942 1,962 1,979 2,020 2,055 2,066 2,090 2,137 2,188 2,226 2,252 2,300
EBITDA 1 332.5 340.6 354.3 379.6 405 399.1 414.2 432.5 448.2 444 453.2 468 481.6 488.1 494.9
EBIT 1 192.9 314 328.6 352.7 377.8 254 209.5 401.1 414.4 294.9 420.5 433.8 445.3 450.3 461.1
Operating Margin 10.23% 16.51% 16.98% 18.16% 19.25% 12.84% 10.37% 19.52% 20.06% 14.11% 19.68% 19.83% 20.01% 20% 20.05%
Earnings before Tax (EBT) 1 91.77 126 130.8 182.2 128.8 131.3 125.2 181.7 186.3 215.8 227.3 250.6 275.3 275.2 279.2
Net income 1 76.47 112 115.7 160.2 117.4 116.7 115.6 163.7 216.4 187.4 194.5 215.9 232.8 235.8 242.9
Net margin 4.06% 5.89% 5.98% 8.25% 5.99% 5.9% 5.72% 7.96% 10.47% 8.97% 9.1% 9.87% 10.46% 10.47% 10.56%
EPS 2 0.9200 1.360 1.410 1.940 1.420 1.410 1.400 1.970 2.600 2.250 2.363 2.585 2.787 2.833 2.933
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/22/22 4/27/22 7/27/22 11/2/22 2/22/23 4/26/23 7/26/23 10/25/23 2/21/24 4/24/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 4,682 4,364 3,396 2,291 1,130 -
Net Cash position 1 220 494 - - - - - 115
Leverage (Debt/EBITDA) - - 4.827 x 2.949 x 2.004 x 1.24 x 0.5602 x -
Free Cash Flow 1 362 517 735 421 1,020 1,215 1,438 1,562
ROE (net income / shareholders' equity) 25.2% 19.2% 13.4% 11.7% 6.9% 12.6% 13.4% 13.6%
ROA (Net income/ Total Assets) 14.2% 10.5% 6.4% 5.6% 3.58% 6.82% 7.44% 7.86%
Assets 1 2,631 3,171 2,394 9,017 17,088 12,307 13,711 14,886
Book Value Per Share 2 30.20 35.10 98.90 104.0 112.0 122.0 134.0 149.0
Cash Flow per Share 2 7.590 10.70 12.40 6.830 14.00 15.00 18.90 20.20
Capex 1 50.6 51.1 93.8 142 141 171 184 195
Capex / Sales 1.8% 1.83% 1.71% 1.84% 1.73% 1.98% 1.99% 1.96%
Announcement Date 2/19/20 2/24/21 2/22/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ICON Public Limited Company

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
308.3 USD
Average target price
354.1 USD
Spread / Average Target
+14.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ICLR Stock
  4. Financials ICON Public Limited Company